Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Fellowship - PA: Respiratory Health - CIHR/CLA/GSK

McGill University

$22,500.00

Prediction of compound synergy in the treatment of inflammatory lung disease

FY 2008-09

Summary
To date there exist no treatments for inflammatory lung diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and standard drugs often fail due to drug resistance, insufficient potency and minimal efficacy. However, combinatorial therapies, where several compounds are used simultaneously, have proven invaluable in the effective treatment of various complex diseases where the overall therapeutic benefit of the drug combination is greater than the sum of positive effects of each drug in isolation. Here we propose a novel approach to predict combinatorial treatments for inflammatory lung diseases based on the analysis of altered gene expression profiles identified in cells treated with individual drugs. With this method, it will be possible to take a shortcut to the identification of potential multi-component therapies, bypassing tedious trial and error experiments testing exponential numbers of drug combinations. First, we will monitor altered gene expression after drug treatment and construct compound-specific patterns from genome-wide experiments. Through the application of bioinformatics/statistical methods we will predict putative synergistic compounds either through similarity or complementation of the cellular patterns generated for a set of CF-specific drugs. Second, we will extend the approach to COPD and adapt a novel screening method to identify compounds therapeutically active in cells from COPD patient lung tissue, generate cellular patterns for each drug identified and apply our statistical method for combinatorial treatment prediction. Decomposing cellular drug responses into specific patterns and developing statistical methods for the comparison of these patterns will allow us to a) identify synergistic compounds with enhanced therapeutic potential for the treatment of multiple inflammatory lung diseases, and b) elucidate underlying unique and common mechanisms between multiple disorders exhibiting related symptoms.
Program
Fellowship - PA: Respiratory Health - CIHR/CLA/GSK
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
173396
Name
Kemmer Danielle
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
GlaxoSmithKline (Mississauga, Ontario); Canadian Lung Association (Ottawa)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Prediction of compound synergy in the treatment of inflammatory lung disease
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$22,500
Cihrequipment2
$0
Programname2
Fellowship - PA: Respiratory Health - CIHR/CLA/GSK
Keyworddelim
Bioinformatics; Functional Genomics; Gene Expression; Inflammatory Lung Disease; Microarray
Abstract
To date there exist no treatments for inflammatory lung diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and standard drugs often fail due to drug resistance, insufficient potency and minimal efficacy. However, combinatorial therapies, where several compounds are used simultaneously, have proven invaluable in the effective treatment of various complex diseases where the overall therapeutic benefit of the drug combination is greater than the sum of positive effects of each drug in isolation. Here we propose a novel approach to predict combinatorial treatments for inflammatory lung diseases based on the analysis of altered gene expression profiles identified in cells treated with individual drugs. With this method, it will be possible to take a shortcut to the identification of potential multi-component therapies, bypassing tedious trial and error experiments testing exponential numbers of drug combinations. First, we will monitor altered gene expression after drug treatment and construct compound-specific patterns from genome-wide experiments. Through the application of bioinformatics/statistical methods we will predict putative synergistic compounds either through similarity or complementation of the cellular patterns generated for a set of CF-specific drugs. Second, we will extend the approach to COPD and adapt a novel screening method to identify compounds therapeutically active in cells from COPD patient lung tissue, generate cellular patterns for each drug identified and apply our statistical method for combinatorial treatment prediction. Decomposing cellular drug responses into specific patterns and developing statistical methods for the comparison of these patterns will allow us to a) identify synergistic compounds with enhanced therapeutic potential for the treatment of multiple inflammatory lung diseases, and b) elucidate underlying unique and common mechanisms between multiple disorders exhibiting related symptoms.
Competitiondate
200810
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Kemmer, Danielle
Approvedterm
2 ans 0 mois
Cihrcontribution2
PDD #351~ $22,500~ $0~